Hyperliquid Unveils HIP-3 Features to Enable Permissioned Markets
Pulmonx chief science officer sells $32,192 in stock By Investing.com
- Investing
Ramit Sethi- 3 minutes read
Srikanth Radhakrishnan, Chief Science & Techn. Officer at Pulmonx Corp (), sold 14,245 shares of common stock on September 1, 2026, for a total value of $32,192. The shares were sold at a price of $2.26 per share.
The transactions included four separate sales, all executed to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). Specifically, Mr. Radhakrishnan sold 2,643 shares for $5,973 in connection with RSUs granted on March 1, 2023. An additional 2,121 shares were sold for $4,793, linked to RSUs granted on March 1, 2024. A third sale involved 3,618 shares for $8,176, covering taxes for RSUs granted on March 3, 2025. Finally, 5,863 shares were sold for $13,250 due to the vesting of RSUs granted on March 2, 2026.
Following these transactions, Mr. Radhakrishnan directly owns 316,994 shares of Pulmonx common stock. The sale comes as LUNG shares have delivered a strong 48% return over the past six months, though InvestingPro analysis suggests the stock remains undervalued at current levels. For deeper insights into Pulmonx’s financial health and comprehensive analysis, investors can access the detailed Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Pulmonx reported financial results for the second quarter of 2026, surpassing analysts’ expectations. The company announced an adjusted loss per share of $0.24, which was better than the anticipated $0.28 loss. Additionally, Pulmonx’s revenue reached $22.8 million, slightly exceeding the forecasted $22.41 million. These results contributed to a notable increase in the company’s stock during after-hours trading. Pulmonx’s performance in the quarter highlights its ability to outpace Wall Street estimates. The financial outcomes were well-received by investors, reflecting positive sentiment towards the company’s recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
